CTLT 241220 45.00C (CTLT241220C45000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CTLT241220C45000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 24 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | S&P Dow Jones Indices: Lennox International to Replace Catalent in S&P 500, & Bill Holdings to Replace Lennox International in S&P MidCap 400
ReutersDec 18 17:47 ET
Express News | Lennox International Set to Join S&P 500 and Bill Holdings to Join S&P MidCap 400
ReutersDec 18 17:46 ET
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400
PR NewswireDec 18 17:46 ET
Express News | Lennox To Replace Catalent In S&P 500, Effective Prior To Opening Of Trading On Monday, December 23
BenzingaDec 18 17:29 ET
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Kevin TraversDec 18 16:16 ET
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Moomoo 24/7Dec 18 15:35 ET

Comments

Stella-K

Jun 19 04:18

Which gets me RICH faster: Growth ETF vs. Dividend ETF Investing

I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA (NVDA.US)$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola (KO.US)$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...

Moomoo News Global

Mar 4 08:15

Columns Eli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?

The pharma giant $Eli Lilly and Co (LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...

100

151364853

Feb 6 12:40

$Catalent(Delisted) (CTLT.US)$ why drop

Iwill TradeScared

Feb 5 22:28

$Catalent(Delisted) (CTLT.US)$ 👀63$ all set target

Moomoo Recap US

Feb 5 15:15

Columns Wall Street Today | Stocks Retreat as Fed in No Rush to Cut

RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index (.SPX.US)$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index (.NDX.US)$ slid 0...

Powell: Not confident rates would lower in March